Publications by authors named "Cheryl L Rowe-Rendleman"

Claim this Profile
R
Regulatory Requirements of Biosimilars: Drug Development in Ophthalmology, Part 1.
Cheryl L Rowe-Rendleman

J Ocul Pharmacol Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulations, Generics, and Disruptive Technologies in Ophthalmology: What Every Scientist Needs to Know.
Cheryl L Rowe-Rendleman, Randolph D Glickman

J Ocul Pharmacol Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
Cheryl L Rowe-Rendleman

Pharm Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making Basic Science Studies in Glaucoma More Clinically Relevant: The Need for a Consensus.
Carol B Toris, Claire Gelfman, Andy Whitlock, William E Sponsel, Cheryl L Rowe-Rendleman

J Ocul Pharmacol Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.
Alon Harris, Caroline L Ward, Cheryl L Rowe-Rendleman, Takafumi Ouchi, Andrew Wood

J Glaucoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers.
Fumitaka Suto, Cheryl L Rowe-Rendleman, Takafumi Ouchi, Alam Jamil, Andrew Wood

Invest Ophthalmol Vis Sci· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug and gene delivery to the back of the eye: from bench to bedside.
Cheryl L Rowe-Rendleman, Shelley A Durazo, Uday B Kompella, Kay D Rittenhouse, Adriana Di Polo

Invest Ophthalmol Vis Sci· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of molecular and genomic biomarkers of retinal drug efficacy: use of ocular fluid sampling to evaluate VEGF.
Rajesh K Sharma, Cheryl L Rowe-Rendleman

Neurochem Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.
Henry F Edelhauser, Cheryl L Rowe-Rendleman, Michael R Robinson, Daniel G Dawson, Gerald J Chader

Invest Ophthalmol Vis Sci· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis